Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accounts Payables: 2016-2025

Historic Accounts Payables for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $28.3 million.

  • Rocket Pharmaceuticals' Accounts Payables fell 23.90% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 23.90%. This contributed to the annual value of $37.8 million for FY2024, which is 17.39% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Accounts Payables stood at $28.3 million, which was down 30.24% from $40.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Accounts Payables' 5-year high stood at $45.8 million during Q4 2023, with a 5-year trough of $17.9 million in Q2 2021.
  • Its 3-year average for Accounts Payables is $34.3 million, with a median of $32.4 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Rocket Pharmaceuticals' Accounts Payables was 86.90% (2022), while the steepest drop was 39.61% (2022).
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Accounts Payables stood at $19.6 million in 2021, then soared by 86.90% to $36.7 million in 2022, then climbed by 24.90% to $45.8 million in 2023, then declined by 17.39% to $37.8 million in 2024, then dropped by 23.90% to $28.3 million in 2025.
  • Its Accounts Payables stands at $28.3 million for Q3 2025, versus $40.5 million for Q2 2025 and $32.4 million for Q1 2025.